6-(isoquinolin-5-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | 1021915-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-(isoquinolin-5-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
• 英文别名: 5-isoquinolin-5-yl-3-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2-one
• CAS: 1021915-53-6
• 化学式: C₂₂H₁₇N₅O
• 分子量: 367.41
• InChiKey: XEPYGEAUHALMSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-bromo-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 、 5-异喹啉硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium phosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以6%的产率得到6-(isoquinolin-5-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
  参考文献：
  名称：

  WO2008/51493

  摘要：

  公开号：

文献信息

• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS
  申请人：Mortensen Deborah Sue

  公开号：US20110245245A1

  公开（公告）日：2011-10-06

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供了具有以下结构的杂环芳基化合物：其中R1、R2、L、X、Y、Z、Q、A和B的定义如下，包括有效量的杂环芳基化合物的组合物，并且治疗或预防癌症、炎症状况、免疫病状况、代谢病状况和通过抑制激酶途径可治疗或预防的病状况的方法包括向需要治疗的患者中施用有效量的杂环芳基化合物。
• Heteroaryl compounds, compositions thereof, and methods of treatment therewith
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2457913A2

  公开（公告）日：2012-05-30

  Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供的是具有以下结构的杂芳基化合物： 其中 R1、R2、L、X、Y、Z、Q、A 和 B 如本文所定义；包含有效量杂芳基化合物的组合物；以及治疗或预防癌症、炎症、免疫学疾病、代谢疾病和可通过抑制激酶通路治疗或预防的疾病的方法，包括向有需要的患者施用有效量杂芳基化合物。
• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2090577B1

  公开（公告）日：2017-04-05
• IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2531194A1

  公开（公告）日：2012-12-12